Literature DB >> 22245210

Dosimetric predictors of radiation-induced acute nausea and vomiting in IMRT for nasopharyngeal cancer.

Victor H F Lee1, Sherry C Y Ng, T W Leung, Gordon K H Au, Dora L W Kwong.   

Abstract

PURPOSE: We wanted to investigate dosimetric parameters that would predict radiation-induced acute nausea and vomiting in intensity-modulated radiation therapy (IMRT) for undifferentiated carcinoma of the nasopharynx (NPC). METHODS AND MATERIALS: Forty-nine consecutive patients with newly diagnosed NPC were treated with IMRT alone in this prospective study. Patients receiving any form of chemotherapy were excluded. The dorsal vagal complex (DVC) as well as the left and right vestibules (VB-L and VB-R, respectively) were contoured on planning computed tomography images. A structure combining both the VB-L and the VB-R, named VB-T, was also generated. All structures were labeled organs at risk (OAR). A 3-mm three-dimensional margin was added to these structures and labeled DVC+3 mm, VB-L+3 mm, VB-R+3 mm, and VB-T+3 mm to account for physiological body motion and setup error. No weightings were given to these structures during optimization in treatment planning. Dosimetric parameters were recorded from dose-volume histograms. Statistical analysis of parameters' association with nausea and vomiting was performed using univariate and multivariate logistic regression.
RESULTS: Six patients (12.2%) reported Grade 1 nausea, and 8 patients (16.3%) reported Grade 2 nausea. Also, 4 patients (8.2%) complained of Grade 1 vomiting, and 4 patients (8.2%) experienced Grade 2 vomiting. No patients developed protracted nausea and vomiting after completion of IMRT. For radiation-induced acute nausea, V40 (percentage volume receiving at least 40Gy) to the VB-T and V40>=80% to the VB-T were predictors, using univariate analysis. On multivariate analysis, V40>=80% to the VB-T was the only predictor. There were no predictors of radiation-induced acute vomiting, as the number of events was too small for analysis.
CONCLUSIONS: This is the first study demonstrating that a V40 to the VB-T is predictive of radiation-induced acute nausea. The vestibules should be labeled as sensitive OARs, and weightings should be considered for dose sparing during optimization in the treatment planning of IMRT.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22245210     DOI: 10.1016/j.ijrobp.2011.10.010

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

Review 1.  2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.

Authors:  Christina H Ruhlmann; Franziska Jahn; Karin Jordan; Kristopher Dennis; Ernesto Maranzano; Alexander Molassiotis; Fausto Roila; Petra Feyer
Journal:  Support Care Cancer       Date:  2016-09-13       Impact factor: 3.603

2.  Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy.

Authors:  Esengul Kocak-Uzel; G Brandon Gunn; Rivka R Colen; Micheal E Kantor; Abdallah S R Mohamed; Sara Schoultz-Henley; Paniyotis Mavroidis; Steven J Frank; Adam S Garden; Beth M Beadle; William H Morrison; Jack Phan; David I Rosenthal; Clifton D Fuller
Journal:  Radiother Oncol       Date:  2014-04-17       Impact factor: 6.280

3.  The ratio of weight loss to planning target volume significantly impacts setup errors in nasopharyngeal cancer patients undergoing helical tomotherapy with daily megavoltage computed tomography.

Authors:  Wei-Hsien Hou; Chun-Wei Wang; Chiao-Ling Tsai; Feng-Ming Hsu; Jason Chia-Hsien Cheng
Journal:  Radiol Oncol       Date:  2016-09-08       Impact factor: 2.991

4.  Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.

Authors:  Victor Ho-Fun Lee; Dora Lai-Wan Kwong; To-Wai Leung; Cheuk-Wai Choi; Vincent Lai; Lydia Ng; Ka-On Lam; Sherry Chor-Yi Ng; Chun-Kin Sze; Chi-Chung Tong; Patty Pui-Ying Ho; Wing-Lok Chan; Lai-San Wong; Dennis Kwok-Chuen Leung; Sum-Yin Chan; Pek-Lan Khong
Journal:  Oncotarget       Date:  2017-01-17

5.  A prospective cohort study of patient-reported vomiting, retching, nausea and antiemetic use during neoadjuvant long-course radiation therapy and concurrent 5-fluorouracil-based chemotherapy for rectal adenocarcinoma.

Authors:  Kristopher Dennis; Liang Zeng; Carlo De Angelis; Hans Chung; Natalie Coburn; Edward Chow; C Shun Wong
Journal:  Clin Transl Radiat Oncol       Date:  2018-04-05

6.  Phase I/II study of induction chemotherapy plus concurrent chemotherapy and SMART-IMRT-based radiotherapy in locoregionally-advanced nasopharyngeal cancer.

Authors:  Ting-Yong Fan; Jun Xing; Jie Lu; Tong-Hai Liu; Min Xu; Ying-Jie Zhang; Qian Shao; Jian-Bin Li; Jin-Ming Yu
Journal:  Oncol Lett       Date:  2013-01-15       Impact factor: 2.967

7.  Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma.

Authors:  Victor H F Lee; Anthony W I Lo; Chun-Yin Leung; Wai-Hung Shek; Dora L W Kwong; Ka-On Lam; Chi-Chung Tong; Chun-Kin Sze; To-Wai Leung
Journal:  PLoS One       Date:  2016-06-24       Impact factor: 3.240

8.  Correlation between delivered radiation doses to the brainstem or vestibular organ and nausea & vomiting toxicity in patients with head and neck cancers - an observational clinical trial.

Authors:  Kilian Schiller; Hanno Martin Specht; Bernhard Haller; Daniela Hallqvist; Michal Devecka; Aaron Becker von Rose; Stephanie Elisabeth Combs; Steffi Pigorsch
Journal:  Radiat Oncol       Date:  2017-07-04       Impact factor: 3.481

9.  Extreme effects of Seabuckthorn extracts on influenza viruses and human cancer cells and correlation between flavonol glycosides and biological activities of extracts.

Authors:  Gansukh Enkhtaivan; K M Maria John; Muthuraman Pandurangan; Ji Hoon Hur; Alain Simplice Leutou; Doo Hwan Kim
Journal:  Saudi J Biol Sci       Date:  2016-01-07       Impact factor: 4.219

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.